LAXA.F Stock Overview
Laxai Pharma, Ltd. offers contract research services in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Laxai Pharma, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | -98.89% |
| 5 Year Change | -93.33% |
| Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LAXA.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -4.1% | -3.2% |
| 1Y | 0% | -6.7% | 19.3% |
Return vs Industry: LAXA.F exceeded the US Life Sciences industry which returned -12.6% over the past year.
Return vs Market: LAXA.F underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| LAXA.F volatility | |
|---|---|
| LAXA.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LAXA.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LAXA.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | n/a |
Laxai Pharma, Ltd. offers contract research services in the United States. It provides integrated services across the drug development spectrum. The company focuses its services in the areas of biostatistics, data management (EDC, Hybrid, and Paper), CDISC consulting, medical writing, monitoring, regulatory, drug safety, and related training programs.
Laxai Pharma, Ltd. Fundamentals Summary
| LAXA.F fundamental statistics | |
|---|---|
| Market cap | US$6.67k |
| Earnings (TTM) | -US$1.91m |
| Revenue (TTM) | US$3.06m |
0.0x
P/S Ratio0.0x
P/E RatioIs LAXA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAXA.F income statement (TTM) | |
|---|---|
| Revenue | US$3.06m |
| Cost of Revenue | US$2.38m |
| Gross Profit | US$676.00k |
| Other Expenses | US$2.58m |
| Earnings | -US$1.91m |
Last Reported Earnings
Sep 30, 2010
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did LAXA.F perform over the long term?
See historical performance and comparison